CPI-444 是一种有效的选择性 A2A 受体 (A2AR) 拮抗剂,诱导抗肿瘤反应。
IN VIVO: CPI-444 treatment resulted in a similar inhibition of tumor growth in the B16F10 melanoma (100 mg/kg) and RENCA renal cell cancer syngeneic models (10 mg/kg). It enhances T-cell activation in both the periphery and tumor microenvironment[1].
上海晴宜生物科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!